193. プラダー・ウィリ症候群 Prader-Willi syndrome Clinical trials / Disease details
臨床試験数 : 113 / 薬物数 : 111 - (DrugBank : 26) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 102
Showing 1 to 3 of 3 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100046551 | 2021-05-18 | 2021-05-21 | Multimodal magnetic resonance imaging changes in Prader-Willi syndrome before and after growth hormone treatment Multimodal magnetic resonance imaging changes in Prader-Willi syndrome before and after growth hormo ... | Application of multimodal magnetic resonance imaging in pre - and post-treatment evaluation of recombinant human growth hormone in children with Prader-Willi syndrome Application of multimodal magnetic resonance imaging in pre - and post-treatment evaluation of recom ... | Prader-Willi sydrome | Prader-Willi sydrome group treated with rhGH:Treat with rhGH;Prader-Willi sydrome group treated without rhGH:Basic medicine;Normal development group:none; Prader-Willi sydrome group treated with rhGH:Treat with rhGH;Prader-Willi sydrome group treated with ... | Cai Jinhua | NULL | Recruiting | 0 | 16 | Both | Prader-Willi sydrome group treated with rhGH:40;Prader-Willi sydrome group treated without rhGH:40;Normal development group:40; | N/A | China |
| 2 | NCT03554031 (ClinicalTrials.gov) | April 14, 2018 | 30/5/2018 | A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth HormoneInjection in Patients ... | A Single Arm, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome A Single Arm, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinan ... | Prader-Willi Syndrome | Drug: Recombinant Human Growth Hormone (rhGH) Injection | GeneScience Pharmaceuticals Co., Ltd. | Children's Hospital of Fudan University;Tongji medical college huazhong university of science & technology;Beijing Children's Hospital;Peking University First Hospital;Peking Union Medical College Hospital;The Children's Hospital of Zhejiang University School of Medicine Children's Hospital of Fudan University;Tongji medical college huazhong university of science & tech ... | Unknown status | 1 Month | 5 Years | All | 30 | Phase 3 | China |
| 3 | EUCTR2017-002164-41-ES (EUCTR) | 03/07/2017 | 21/06/2017 | Study with adult patients with Prader-Willi syndrome, which evaluate the effect of growth hormone therapy on muscle tone and its relation with muscle strength and body composition assessed with imaging procedures. Study with adult patients with Prader-Willi syndrome, which evaluate the effect of growth hormone th ... | Growth hormone therapy in adults with Prader-Willi syndrome: Effect on muscle tone assessed by functional magnetic resonance imaging (fMRI) and its relation to muscle strenght and body composition. Growth hormone therapy in adults with Prader-Willi syndrome: Effect on muscle tone assessed by funct ... | Patients with Prader-Willi Syndrome (SPW) with Growth hormone deficit. MedDRA version: 20.0;Level: PT;Classification code 10036476;Term: Prader-Willi syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19] Patients with Prader-Willi Syndrome (SPW) with Growth hormone deficit. MedDRA version: 20.0;Level: P ... | Trade Name: Genotonorm Miniquick 0,2 mg INN or Proposed INN: RECOMBINANT HUMAN GROWTH HORMON Other descriptive name: RECOMBINANT HUMAN GROWTH HORMONE Trade Name: Genotonorm Miniquick 0,2 mg INN or Proposed INN: RECOMBINANT HUMAN GROWTH HORMON Other des ... | Fundació Parc Taulí | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Phase 4 | Spain |